- Home
- TEN vs ATXS Comparison
TEN vs ATXS Comparison
Compare TEN & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- ATXS
- Stock Information
- Founded
- TEN 1993
- ATXS 2008
- Country
- TEN Greece
- ATXS United States
- Employees
- TEN N/A
- ATXS N/A
- Industry
- TEN
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- TEN
- ATXS Health Care
- Exchange
- TEN NYSE
- ATXS Nasdaq
- Market Cap
- TEN 480.8M
- ATXS 401.2M
- IPO Year
- TEN N/A
- ATXS 2015
- Fundamental
- Price
- TEN $17.51
- ATXS $4.23
- Analyst Decision
- TEN Buy
- ATXS Strong Buy
- Analyst Count
- TEN 2
- ATXS 6
- Target Price
- TEN $31.00
- ATXS $30.00
- AVG Volume (30 Days)
- TEN 257.9K
- ATXS 498.3K
- Earning Date
- TEN 05-23-2025
- ATXS 05-20-2025
- Dividend Yield
- TEN 8.56%
- ATXS N/A
- EPS Growth
- TEN N/A
- ATXS N/A
- EPS
- TEN 5.03
- ATXS N/A
- Revenue
- TEN $804,061,000.00
- ATXS N/A
- Revenue This Year
- TEN N/A
- ATXS N/A
- Revenue Next Year
- TEN $11.19
- ATXS N/A
- P/E Ratio
- TEN $3.42
- ATXS N/A
- Revenue Growth
- TEN N/A
- ATXS N/A
- 52 Week Low
- TEN $13.40
- ATXS $3.56
- 52 Week High
- TEN $31.48
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- TEN 58.95
- ATXS 36.98
- Support Level
- TEN $17.02
- ATXS $5.01
- Resistance Level
- TEN $17.73
- ATXS $5.47
- Average True Range (ATR)
- TEN 0.57
- ATXS 0.39
- MACD
- TEN 0.14
- ATXS -0.01
- Stochastic Oscillator
- TEN 78.47
- ATXS 7.81
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.